EMA just released the new dossier requirements for Centrally Authorized Products (CAPs). Effective, tomorrow 1 July 2015, all CAP submissions to CHMP members should now be sent via the EMA eSubmission Gateway. This means that all CHMP members will be able to access the submissions via the Common Repository.
South Africa (ZA-MCC) has a plan to start accepting dossier in eCTD format, From 1st June 2015 eCTD is open for entire industry.
The Agency for Medicines and Medical Devices BiH announced acceptance of documents for methods of administering / changes / renewal of the authorization in NeeS format. ALMBIH will accept NeeS submissions for any type of submissions relating to regulatory affairs, including: granting licenses, renewal, variation, transfer or revocation / withdrawal of the license, PSUR and […]
The eCTD version 4.0 EU M1 Implementation Guide is now available for public consultation, and the eSubmission Change Management Board invites all pharmaceutical companies, vendors of eCTD building and reviewing tools and competent authorities to take part in this consultation and provide comments by 22 May 2015.
The ICH M8 EWG was formed in November 2010 to assume responsibility for the continued development of the next major version of the eCTD. The M8 EWG has developed the draft of the ICH eCTD v4.0 Implementation Guide. This guide is now being made available as DRAFT Version 2.0 along with the draft ICH Code […]
The US Food and Drug Administration”s (FDA) Center for Drug Evaluation and Research (CDER) has released a new list of 90 guidance documents it plans to publish in 2015, including several long anticipated and eagerly awaited by members of the pharmaceutical industry.
FDA released GDUID Health Level 7 (HL7) Structured Product Labeling (SPL) Implementation Specification V1.3
From June 20, 2014, the US FDA Stability guidance for ANDA submission will require 3 batches for every strength (three industrial scale or two industrial and one lab scale) and 6 months of accelerated stability
USFDA has announced new drug registration guidelines of pharmaceutical product for eCTD submission- Module 1 Specification version 2.3 and eCTD Validation Criteria, version 3.1. This guideline will be implement from last quarter of current year (2014)
In January 2013, CESG is part of ESG for regulatory submission of medicinal product to Canada means Health Canada is participating with the USFDA, to reduce regulatory burden for health products as part of the Canada-U.S. If you are already registered with the FDA as a Trading Partner and now wish to do business with […]